Navigation Links
University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence

ST. JOSEPH, Mich., July 16 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Miami Miller School of Medicine has become a certified GeneGo Center of Excellence (COE). Miller School of Medicine researchers will have access to GeneGo's MetaCore, training and advanced support. COE will provide a pathway analysis environment and support for all the school's researchers. They will also act as a training facility for GeneGo in the University of Miami.

"We are looking forward to working with GeneGo as the company provides the kind of forward-looking bioinformatics software that we are excited to use," said Sawsan Khuri, Ph.D., assistant research professor at the Center for Computational Science at the University of Miami Miller School of Medicine. "The technology will be extremely useful for researchers here, especially those at the Miami Project to Cure Paralysis and the Miami Institute for Human Genomics, both of which will benefit greatly from the collaboration with GeneGo as we work toward new scientific breakthroughs."

"The University of Miami has some important thought leaders in this field and we are pleased to be working with them," said Julie Bryant, Vice President of Business Development at GeneGo. "The school of medicine works with one million patients annually and it is encouraging that we can help them to improve their quality of life."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
2. Most developing countries ill-equipped to ensure global biosafety: UN University
3. Nanocopoeia Licenses New Polymer-Based Biomaterials Platform From the University of Western Ontario
4. University of Pennsylvania engineers reveal what makes diamonds slippery at the nanoscale
5. Court Determines that University of Pittsburgh and Artecel Have Sole Rights to Adipose-Derived Stem Cell Patent
6. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
7. Nikon Instruments Opens New Imaging Center at Northwestern University
8. Most developing countries ill-equipped to ensure global biosafety: UN University
9. Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine
10. University Research and Science Parks Create Sustainable Innovation
11. University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):